KRE vs XBI
SPDR S&P Regional Banking ETF vs SPDR S&P Biotech ETF
- • KRE pays a higher dividend yield (2.25%).
Side-by-side metrics
| Metric | KRE | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.35% | 0.35% |
Dividend yield Trailing 12-month yield. | 2.25% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $4.17B | $8.30B |
YTD return | 9.73% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.31 | 1.09 |
P/E ratio | 12.56 | — |
Last price | $69.95 | $133.66 |
Inception | — | — |
Issuer | State Street | State Street |
KRE top holdings
| EWBC | East West Bancorp Inc | 1.63% |
| WAL | Western Alliance Bancorp | 1.60% |
| BPOP | Popular Inc | 1.59% |
| PNFP | Pinnacle Financial Partners Inc | 1.59% |
| ZION | Zions Bancorp NA | 1.58% |
| VLY | Valley National Bancorp | 1.55% |
| ASB | Associated Banc-Corp | 1.55% |
| UMBF | UMB Financial Corp | 1.54% |
| FLG | Flagstar Bank NA | 1.54% |
| TFC | Truist Financial Corp | 1.54% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About KRE
KRE (SPDR S&P Regional Banking ETF) is US regional bank stocks. Managed by State Street, the fund carries $4.2B in assets under management, an expense ratio of 0.35%, a dividend yield of 2.25%. Its largest holding is East West Bancorp Inc (EWBC), which represents 1.6% of the portfolio. Financial Services is the fund's largest sector exposure at 100.0%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.